NOVELIX PHARMACEUTICALS LIMITE Stock Price Today (NSE: NOVELIX)
NOVELIX PHARMACEUTICALS LIMITE
Fundamental Score
NOVELIX PHARMACEUTICALS LIMITE Share Price — Live NSE/BSE Price, Fundamentals & Analysis
NOVELIX PHARMACEUTICALS LIMITE share price today is ₹74.14, down 4.34% on NSE/BSE as of 22 September 2026. NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹156.32 (Cr). The 52-week high for NOVELIX share price is ₹92.00 and the 52-week low is ₹38.00. At a P/E ratio of 43.03x, NOVELIX is currently trading above its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 8.00% and a debt-to-equity ratio of 0.09.
NOVELIX PHARMACEUTICALS LIMITE Share Price Chart — NSE/BSE Historical Performance
NOVELIX PHARMACEUTICALS LIMITE share price chart: 6.48% return over the past month. 52-week high ₹92.00, 52-week low ₹38.00.
NOVELIX PHARMACEUTICALS LIMITE — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹82.00 | ₹82.00 | ₹73.00 | ₹77.50 | 4.23K (Cr) | |
| ₹81.99 | ₹81.99 | ₹78.00 | ₹78.26 | 1.90K (Cr) | |
| ₹77.00 | ₹79.20 | ₹76.00 | ₹78.16 | 800.00 (Cr) | |
| ₹79.88 | ₹81.99 | ₹76.00 | ₹79.51 | 11.76K (Cr) | |
| ₹80.00 | ₹80.00 | ₹73.70 | ₹79.88 | 8.11K (Cr) | |
| ₹78.00 | ₹78.00 | ₹71.60 | ₹77.50 | 926.00 (Cr) | |
| ₹78.50 | ₹78.50 | ₹74.35 | ₹75.01 | 1.21K (Cr) | |
| ₹78.10 | ₹80.00 | ₹78.10 | ₹78.10 | 3.58K (Cr) | |
| ₹79.00 | ₹79.00 | ₹76.80 | ₹76.80 | 496.00 (Cr) | |
| ₹78.10 | ₹80.35 | ₹77.10 | ₹77.49 | 5.19K (Cr) |
NOVELIX PHARMACEUTICALS LIMITE — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹82.00 | ₹82.00 | ₹71.60 | ₹77.50 | -5.49% | |
| ₹69.49 | ₹83.99 | ₹67.00 | ₹80.50 | +15.84% | |
| ₹79.00 | ₹80.65 | ₹63.19 | ₹69.49 | -12.04% | |
| ₹53.60 | ₹92.00 | ₹51.00 | ₹76.85 | +43.38% | |
| ₹56.00 | ₹58.80 | ₹50.60 | ₹56.00 | +0.00% | |
| ₹58.00 | ₹64.80 | ₹49.01 | ₹55.03 | -5.12% | |
| ₹60.40 | ₹62.95 | ₹50.00 | ₹55.78 | -7.65% | |
| ₹60.31 | ₹68.69 | ₹58.00 | ₹60.47 | +0.27% | |
| ₹61.01 | ₹62.90 | ₹51.30 | ₹60.42 | -0.97% | |
| ₹63.00 | ₹69.35 | ₹51.25 | ₹62.62 | -0.60% | |
| ₹52.20 | ₹70.16 | ₹49.26 | ₹60.01 | +14.96% | |
| ₹39.70 | ₹57.65 | ₹38.00 | ₹53.05 | +33.63% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
NOVELIX PHARMACEUTICALS LIMITE Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
NOVELIX PHARMACEUTICALS LIMITE Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NOVELIX across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Robust Profit Growth (1002.80%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (65.14%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (151.69% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (18.13% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (22.72% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.09)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 2.79)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (50.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (8.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.97%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 43.03x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-43.41 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
NOVELIX PHARMACEUTICALS LIMITE vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare NOVELIX PHARMACEUTICALS LIMITE with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC...Selected✓ NOVELIX • 536565 | 56.9/100 | ₹74.14₹74 | ₹156.32₹156.32 | 43.03Average 43.0 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Syngene International LimitedSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹386.80₹387 | ₹15615.12₹15615.12 | 70.33Average 70.3 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Indegene LimitedIndegene Limite... INDGN • 544172 | 57/100 | ₹586.35₹586 | ₹14101.72₹14101.72 | 35.09Average 35.1 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Suven Life Sciences LimitedSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹357.50₹358 | ₹9437.75₹9437.75 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LimitedVimta Labs Limi... VIMTALABS • 524394 | 63.6/100 | ₹628.15₹628 | ₹2805.95₹2805.95 | 35.17Average 35.2 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
TAKE LimitedTAKE Limited... TAKE • 532890 | 31.2/100 | ₹15.99₹16 | ₹236.55₹236.55 | 18.59Average 18.6 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹91.66₹92 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Limited share price15615.12 Cr
- Indegene Limited share price14101.72 Cr
- Suven Life Sciences Limited share price9437.75 Cr
- Vimta Labs Limited share price2805.95 Cr
- TAKE Limited share price236.55 Cr
NOVELIX PHARMACEUTICALS LIMITE PE Ratio History
Historical price-to-earnings ratio for NOVELIX — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.01 | ₹24.15 | 2415x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
NOVELIX PHARMACEUTICALS LIMITE Quarterly Performance
Latest quarterly metrics for NOVELIX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
65.14%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1002.80%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
151.69%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
22.72%
Compounded annual net profit growth over 5 years
NOVELIX PHARMACEUTICALS LIMITE Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NOVELIX — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
NOVELIX PHARMACEUTICALS LIMITE Financial Statements
Annual income statement, balance sheet and cash flow for NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for NOVELIX PHARMACEUTICALS LIMITE
About NOVELIX (NOVELIX PHARMACEUTICALS LIMITE)
NOVELIX PHARMACEUTICALS LIMITE is an emerging force within the healthcare sector, strategically positioned at the intersection of cutting-edge research, sophisticated analytics, an...d innovative technology. While rooted in pharmaceutical trading and related product distribution within India, NOVELIX is rapidly evolving beyond its traditional scope. The company is actively investing in advanced data analytics capabilities to extract actionable insights from complex healthcare datasets. This focus includes developing predictive models to optimize drug development processes, personalize treatment strategies, and identify emerging trends in disease prevalence and patient outcomes. NOVELIX envisions leveraging these analytical strengths to become a pivotal partner in advancing precision medicine and improving healthcare accessibility. Furthermore, NOVELIX is committed to integrating technology into all facets of its operations, from streamlining supply chains to enhancing patient engagement. The company is exploring opportunities in areas like telehealth, remote patient monitoring, and AI-driven diagnostic tools. This technological drive is aimed at creating a more efficient, responsive, and patient-centric healthcare ecosystem. By fostering collaborations with technology startups and research institutions, NOVELIX seeks to be at the forefront of healthcare innovation. This includes actively pursuing novel drug delivery systems and advanced therapeutic interventions, pushing the boundaries of medical science and transforming patient care. The transformation of NOVELIX reflects a strategic shift toward becoming a key player in the next generation of healthcare solutions. Building on its established presence in the Indian pharmaceutical market, NOVELIX is channeling resources into building a robust platform for data-driven decision-making and technology-enabled healthcare services. The company understands that the future of healthcare relies on the seamless integration of data, technology, and medical expertise, and NOVELIX is determined to be a driving force in shaping that future. With a renewed focus on research and development, NOVELIX aims to contribute meaningfully to advancements in healthcare outcomes and improve the lives of patients across India and beyond.
Company Details
Key Leadership
NOVELIX Share Price: Frequently Asked Questions
What is the current share price of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) trades at ₹74.14 on NSE and BSE. Market cap ₹156.32 (Cr). Educational data only.
What is the P/E ratio of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a P/E of 43.03x vs industry average 39.78x.
What is the Bull Run score for NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a Bull Run score of 56.9/100 based on 25+ financial parameters.
Does NOVELIX PHARMACEUTICALS LIMITE pay dividends?
NOVELIX PHARMACEUTICALS LIMITE has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has ROE of 8.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has debt-to-equity of 0.09.
Is NOVELIX PHARMACEUTICALS LIMITE a good investment?
Bull Run gives NOVELIX PHARMACEUTICALS LIMITE a score of 56.9/100. This is not investment advice — consult a SEBI-registered advisor.